Actuate Therapeutics will present top-line Erluglusive Phase 2 data at the ASCO 2025 Annual Meeting.

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.